Physician profile
Tohru Sato
NPI 1497847248
$1,888.67
in general payments reported to CMS, 2019-2025
12 companies · $1,138 in 2025
The $1,138 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $110 · 2022: $125 · 2023: $269 · 2024: $247 · 2025: $1,138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,653.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,653.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $677.75 | 2019-2025 | Rinvoq |
| Lilly USA, LLC | $407.30 | 2024-2025 | Omvoh |
| Madrigal Pharmaceuticals | $223.24 | 2025 | Rezdiffra |
| E.R. Squibb & Sons, L.L.C. | $149.61 | 2023 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $99.01 | 2025 | Xifaxan |
| Janssen Biotech, INC. | $73.50 | 2025 | Tremfya |
| Aimmune Therapeutics, INC. | $62.67 | 2025 | Zenpep, Vowst |
| Ardelyx, INC. | $56.24 | 2025 | Ibsrela |
| Celltrion USA INC. | $53.95 | 2025 | Vegzelma |
| Phathom Pharmaceuticals, INC. | $45.97 | 2025 | Voquezna |
| Novo Nordisk INC | $19.95 | 2025 | Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $19.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tohru Sato listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.